THE EFFECTS OF CYP3A INDUCTION AND INHIBITION ON ZURANOLONE PHARMACOKINETICS IN HEALTHY ADULTS

被引：0
|
作者：
Dunbar, J. [1 ]
Srinivas, N. [1 ]
Hoffmann, E. [1 ]
机构：
[1] Sage Therapeut, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-089
引用
收藏
页码：S71 / S72
页数：2
相关论文
共 50 条
  • [1] CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokinetics
    Bhat, Laxminarayan
    Bhat, Seema R.
    Ramakrishnan, Arulprakash
    Kulanthaivel, Palaniappan
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [2] Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults
    Boinpally, Ramesh
    Chen, Wayne
    Mcgeeney, Danielle
    Trugman, Joel M.
    PAIN MANAGEMENT, 2023,
  • [3] Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
    Tugnait, Meera
    Gupta, Neeraj
    Hanley, Michael J.
    Sonnichsen, Daryl
    Kerstein, David
    Dorer, David J.
    Venkatakrishnan, Karthik
    Narasimhan, Narayana
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 214 - 223
  • [4] The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator
    Elgart, Anna
    Greenblatt, David J.
    Loupe, Pippa S.
    Zur, Arik A.
    Weiss, Sivan
    Mimrod, Dorit
    Spiegelstein, Ofer
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 1015 - 1024
  • [5] Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
    Li, Xiaoyan
    Shelton, Mark J.
    Wang, Jing
    Meade, Julie
    Ruiz-Soto, Rodrigo
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (10): : 1165 - 1176
  • [6] Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers
    Wong, SL
    Cao, G
    Mack, R
    Granneman, GR
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1998, 36 (03) : 146 - 151
  • [7] Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol
    Bui, Khanh
    Zhou, Diansong
    Sostek, Mark
    She, Fahua
    Al-Huniti, Nidal
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 1019 - 1027
  • [8] Effects of ursodeoxycholic acid on the CYP3A activity and pharmacokinetics of midazolam in rats and healthy volunteers
    Uchida, Shinya
    Kurosawa, Shohei
    Misaka, Shingen
    Yamada, Shizuo
    Watanabe, Hiroshi
    Ohashi, Kyoichi
    DRUG METABOLISM REVIEWS, 2006, 38 : 54 - 54
  • [9] Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
    Eisenmann, Eric D.
    Fu, Qiang
    Muhowski, Elizabeth M.
    Jin, Yan
    Uddin, Muhammad Erfan
    Garrison, Dominique A.
    Weber, Robert H.
    Woyach, Jennifer A.
    Byrd, John C.
    Sparreboom, Alex
    Baker, Sharyn D.
    CANCER RESEARCH COMMUNICATIONS, 2021, 1 (02): : 79 - 89
  • [10] The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole
    Kovarik, John M.
    Huang, Hsun-Lun A.
    Slade, Alan
    Sfikas, Nikos
    Chandler, Patricia A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (03) : 381 - 385
12345